Insights on Atrial Fibrillation in Congenital Heart Disease

Can J Cardiol. 2018 Nov;34(11):1531-1533. doi: 10.1016/j.cjca.2018.08.010. Epub 2018 Aug 14.

Abstract

Patients with congenital heart disease (CHD) have been surviving late into adulthood, with atrial arrhythmias being the most common long-term complication. In recent reports, atrial fibrillation (AF) tended to be the most common form of arrhythmias among groups of patients with adult CHD (ACHD) older than 50 years of age. When compared with their adult counterparts without CHD, AF in patients with ACHD has been characterized by a higher incidence and prevalence, younger age of onset, and a greater risk of progression to persistent AF. Risk factors for the development of AF are not well known but include older age, left atrial dilation, systemic hypertension, and multiple cardiac surgeries. Data on management options such as optimal antiarrhythmic drug therapy, indications for anticoagulation, and efficacy and safety of catheter ablation are limited. There is a crucial need for further research exploring management, prevention, and monitoring strategies for the growing ACHD patient population with AF. This report will provide a contemporary review of the epidemiology, pathophysiology, and management options for AF in this complex patient population.

Publication types

  • Review

MeSH terms

  • Age of Onset
  • Anti-Arrhythmia Agents / therapeutic use
  • Anticoagulants / therapeutic use
  • Atrial Fibrillation / epidemiology*
  • Atrial Fibrillation / physiopathology
  • Atrial Fibrillation / therapy*
  • Catheter Ablation
  • Disease Progression
  • Heart Defects, Congenital / epidemiology*
  • Heart Defects, Congenital / physiopathology
  • Humans
  • Risk Factors
  • Stroke / prevention & control
  • Thrombosis / prevention & control

Substances

  • Anti-Arrhythmia Agents
  • Anticoagulants